Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Heron Therapeutics (HRTX)
Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,478
  • Shares Outstanding, K 140,759
  • Annual Sales, $ 107,670 K
  • Annual Income, $ -182,020 K
  • 60-Month Beta 0.98
  • Price/Sales 1.31
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HRTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.17
  • Most Recent Earnings -0.35 on 08/14/23
  • Next Earnings Date 11/14/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 70.13% ( -3.84%)
  • Historical Volatility 55.85%
  • IV Percentile 13%
  • IV Rank 20.24%
  • IV High 260.46% on 06/12/23
  • IV Low 21.82% on 09/15/23
  • Put/Call Vol Ratio 3.75
  • Today's Volume 19
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 24,366
  • Open Int (30-Day) 26,933

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.33
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +18.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9313 +4.16%
on 09/28/23
1.7250 -43.77%
on 09/01/23
-0.7000 (-41.92%)
since 08/28/23
3-Month
0.9313 +4.16%
on 09/28/23
1.8700 -48.13%
on 08/10/23
-0.2150 (-18.14%)
since 06/28/23
52-Week
0.9313 +4.16%
on 09/28/23
4.6800 -79.27%
on 10/04/22
-3.5200 (-78.40%)
since 09/28/22

Most Recent Stories

More News
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 0.9700 (-2.11%)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 0.9700 (-2.11%)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by...

HRTX : 0.9700 (-2.11%)
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 0.9700 (-2.11%)
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 25% and 24.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 7.88 (-1.25%)
HRTX : 0.9700 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 1.0716
2nd Resistance Point 1.0358
1st Resistance Point 1.0029
Last Price 0.9700
1st Support Level 0.9342
2nd Support Level 0.8984
3rd Support Level 0.8655

See More

52-Week High 4.6800
Fibonacci 61.8% 3.2480
Fibonacci 50% 2.8056
Fibonacci 38.2% 2.3633
Last Price 0.9700
52-Week Low 0.9313

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar